November 22, 2019
Johnson & Johnson's Jansen pharmaceutical subsidiary will launch the company's first-ever solely digital trial to test a potential new use for its diabetes drug Invokana, the company announced last weekend at the American Heart Association conference.
American Health Line rounds up the latest health care news in the states.
November 21, 2019
Stephen Hahn, President Trump's nominee for FDA commissioner, on Wednesday faced questions from lawmakers on the Senate Health, Education, Labor and Pensions Committee regarding drug shortages and prices, e-cigarette use, and more.
November 20, 2019
While patients with health insurance receive the influenza shot at no cost to them, the common health care service serves as an example of how opaqueness in health care pricing can cost patients in the long run, according to a Kaiser Health News analysis.
Sens. Cory Booker (D-N.J.), Kamala Harris (D-Calif.), and Bernie Sanders (I-Vt.), who are competing for the 2020 Democratic presidential nomination, on Friday introduced a bill that would establish a new federal agency to regulate prescription drug prices.
HHS on Monday announced the rate of improper Medicare fee-for-service payments in fiscal year (FY) 2019 was at the lowest point since FY 2010.
November 19, 2019
A large, federally funded study found bypass surgeries and stents are not more effective than cholesterol-lowering drugs or healthy habits at preventing heart attacks and deaths, researchers announced Saturday at the American Heart Association's annual meeting—findings that call into question the care of thousands of patients with blocked coronary arteries.
Sens. Bernie Sanders (I-Vt.) and Elizabeth Warren (D-Mass.), who each are seeking the 2020 Democratic nomination for president, on Friday separately announced timelines for implementing their so-called "Medicare-for-All" proposals if they are elected president.
November 18, 2019
TIME on Wednesday released its first TIME 100 Next list, naming the 100 "rising stars who are shaping the future of business, entertainment, sports, politics, science, health, and more."
Large, brand-name drugmakers could lose $1 trillion in sales and still remain profitable enough to maintain their current investments in research and development—a finding that suggests drug pricing regulations would not substantially harm the drug industry, according to a report released Thursday by West Health and Johns Hopkins Bloomberg School of Public Health.
Advisory Board. All rights reserved.